Concord Wealth Partners Blueprint Medicines Corp Transaction History
Concord Wealth Partners
- $673 Million
- Q2 2025
A detailed history of Concord Wealth Partners transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Concord Wealth Partners holds 1 shares of BPMC stock, worth $129. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$129% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
389Shares Held
66.9MCall Options Held
973KPut Options Held
1.54M-
Black Rock Inc. New York, NY6.65MShares$861 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.42MShares$831 Million0.01% of portfolio
-
Pentwater Capital Management LP Naples, FL3.9MShares$505 Million3.34% of portfolio
-
Jpmorgan Chase & CO New York, NY2.51MShares$324 Million0.02% of portfolio
-
State Street Corp Boston, MA2.23MShares$289 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $7.73B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...